Delving into the Latest Updates on HOV-12020 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesCongenital Disorders+ [1]

Active Indication-

Inactive Indication

CadasilCerebral Autosomal Dominant Arteriopathy and Subcortical Infarcts and Leukoencephalopaty (CADASIL)

Originator Organization

Hovid Bhd.

Active Organization-

Inactive Organization

Hovid Bhd.

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

A study using Parkinson's disease animal model, transgenic fruit flies, demonstrated the potential of using tocotrienols (HOV-12020) as a therapeutic agent for delaying Parkinsonian motor dysfunctions. The proposed study aims to enrol 100 PD patients in a randomized placebo-controlled trial to investigate the effects of tocotrienols (HOV-12020) in motor and non-motor outcomes. Patients will be given oral tocotrienols (400mg/day) or placebo for 104 weeks. They will be assessed using the standard assessments scales in PD at baseline, Week 52 and Week 104. Neuropsychological evaluation will also be completed at these intervals to monitor progression of cognitive impairment (if any). Additional PD staging using MDSUPDRS (Part III), Hoehn & Yahr (H&Y) will be conducted at Week 26 and week 78. Blood samples will be collected to evaluate PD biomarkers and for safety monitoring (liver function, renal function and hematology).

Start Date01 Apr 2021

Sponsor / Collaborator-

NCT04658823

/ Unknown statusPhase 2

A Randomized Placebo-controlled Double-blind Pilot / Phase II Study to Assess the Efficacy and Safety of HOV-12020 in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)

CADASIL is a paradigmatic cerebral small vessel disease responsible for white-matter lesions, accumulation of lacunes, microbleeds and cerebral atrophy. The disease is responsible for stroke and cognitive decline associated with motor disability. The number of incident lacunes, and amount of cerebral atrophy were recently found to have a strong relationship to cognitive decline and disability progression over 3 years in a large sample of patients. Palm tocotrienols has previously shown evidence of therapeutic effect in attenuating the progression of WMH related to sporadic cerebral small vessel disease in a randomized controlled clinical trial. We hypothesize that palm tocotrienols complex (HOV-12020) can reduce the clinical progression in CADASIL.

Start Date21 Dec 2020

Sponsor / Collaborator

Hovid Bhd.

100 Clinical Results associated with HOV-12020

Login to view more data

100 Translational Medicine associated with HOV-12020

Login to view more data

100 Patents (Medical) associated with HOV-12020

Login to view more data

100 Deals associated with HOV-12020

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cadasil	Phase 2	FR	Hovid Bhd.	21 Dec 2020
Cerebral Autosomal Dominant Arteriopathy and Subcortical Infarcts and Leukoencephalopaty (CADASIL)	Phase 2	FR	Hovid Bhd.	21 Dec 2020